Author:
Markham Anthony,Duggan Sean
Publisher
Springer Science and Business Media LLC
Reference13 articles.
1. Follmann M, Ackerstaff J, Redlich G, et al. Discovery of the soluble guanylate cyclase stimulator vericiguat (BAY 1021189) for the treatment of chronic heart failure. J Med Chem. 2017;60(12):5146–61.
2. Lang NN, Dobbin SJH, Petrie MC. Vericiguat in worsening heart failure: agonising over, or celebrating, agonism in the VICTORIA trial. Cardiovasc Res. 2020;116(12):e152–5.
3. Armstrong PW, Pieske B, Anstrom KJ, et al. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med. 2020;382(20):1883–93.
4. Merck & Co. VERQUVOTM (vericiguat) tablets, for oral use. 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214377s000lbl.pdf. Accessed 19 Feb 2021.
5. Merck AG. Merck announces U.S. FDA approval of VERQUVO® (vericiguat) [media release]. 20 Jan 2021. http://www.merck.com.
Cited by
41 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献